Search

Pizotifen

Sandomigran is available in a number of countries but is not approved by the FDA nor EMA. … [A32532] It is a potent serotonin and tryptamine antagonist that has been used for migraine prevention for many years.

Noscapine

Romidepsin

Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy

Zosuquidar

Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States.

Icatibant

Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B₂ receptors with a similar affinity to bradykinin. … It is resistant to bradykinin-cleaving enzyme degradation and has a potency of 2-3 times higher than earlier B₂ receptors antagonists, thus representing a new class of medication.

Sugammadex

Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. … Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery.

Arzoxifene

Sitaxentan

Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan f...

Ziconotide

Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds.

Saxagliptin

Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.